- Home
- TRMD vs GLPG Comparison
TRMD vs GLPG Comparison
Compare TRMD & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- GLPG
- Stock Information
- Founded
- TRMD 1889
- GLPG 1999
- Country
- TRMD United Kingdom
- GLPG Belgium
- Employees
- TRMD N/A
- GLPG N/A
- Industry
- TRMD Marine Transportation
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- TRMD Consumer Discretionary
- GLPG Health Care
- Exchange
- TRMD Nasdaq
- GLPG Nasdaq
- Market Cap
- TRMD 2.0B
- GLPG 2.1B
- IPO Year
- TRMD N/A
- GLPG 2005
- Fundamental
- Price
- TRMD $20.99
- GLPG $34.31
- Analyst Decision
- TRMD Buy
- GLPG Sell
- Analyst Count
- TRMD 1
- GLPG 3
- Target Price
- TRMD $23.00
- GLPG $26.00
- AVG Volume (30 Days)
- TRMD 577.5K
- GLPG 222.3K
- Earning Date
- TRMD 11-06-2025
- GLPG 11-03-2025
- Dividend Yield
- TRMD 12.56%
- GLPG N/A
- EPS Growth
- TRMD N/A
- GLPG N/A
- EPS
- TRMD 3.31
- GLPG N/A
- Revenue
- TRMD $1,321,800,000.00
- GLPG $323,674,692.00
- Revenue This Year
- TRMD N/A
- GLPG $1.77
- Revenue Next Year
- TRMD N/A
- GLPG $0.44
- P/E Ratio
- TRMD $6.04
- GLPG N/A
- Revenue Growth
- TRMD N/A
- GLPG 5.43
- 52 Week Low
- TRMD $13.60
- GLPG $22.36
- 52 Week High
- TRMD $30.20
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- TRMD 50.74
- GLPG 52.88
- Support Level
- TRMD $20.13
- GLPG $33.91
- Resistance Level
- TRMD $20.79
- GLPG $35.00
- Average True Range (ATR)
- TRMD 0.48
- GLPG 0.79
- MACD
- TRMD -0.01
- GLPG -0.15
- Stochastic Oscillator
- TRMD 62.17
- GLPG 25.38
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Engineering segment. The company derives maximum revenue from Tanker segment.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.